Relevant conflicts of interest/financial disclosures: Dr. Reilmann provided consulting services, advisory board functions, clinical trial services, quantitative motor analyses, and/or lectures for Novartis, Teva, Siena Bitoech, Neurosearch Inc., Medivation/Pfizer, Lundbeck, Ipsen, Wyeth, ISIS Pharma, Link Medicine, Prana Biotechnology, the Cure Huntington's Disease Initiative Foundation, MEDA, Temmler Pharma, and AOP Orphan Pharmaceuticals AG. He serves on the Advisory Board of the “Jacques and Gloria Gossweiler Foundation” and has several responsibilities in the European Huntington's Disease Network (member of the “Executive Committee” and the “Clinical Trials Task Force”, Lead Facilitator of the Neuroprotective Therapy and Motor Phenotype Working Groups) and serves as Global Coordinating Principle Investigator of clinical trials. Dr. Reilmann received grant support from the High-Q-Foundation, the Cure Huntington's Disease Initiative Foundation (CHDI), the Deutsche Forschungsgemeinschaft (DFG), the European Union (EU-FP7 program) and the European Huntington's Disease Network (EHDN).
The pridopidine paradox in Huntington's disease
Article first published online: 11 JUL 2013
© 2013 International Parkinson and Movement Disorder Society
Volume 28, Issue 10, pages 1321–1324, September 2013
How to Cite
Reilmann, R. (2013), The pridopidine paradox in Huntington's disease. Mov. Disord., 28: 1321–1324. doi: 10.1002/mds.25559
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 23 SEP 2013
- Article first published online: 11 JUL 2013
- Manuscript Accepted: 10 MAY 2013
- Manuscript Revised: 5 MAY 2013
- Manuscript Received: 20 FEB 2013